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Abstract
Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately 
resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. 
Nivolumab, a fully human IgG4 anti-PD-1 antibody, selectively blocks the interaction between PD-1 and its ligands PD-L1 and 
PD-L2 and provides a novel therapy option for patients with aRCC. In 2015, the pivotal phase III study CheckMate 025 led to the 
Food and Drug Administration approval of nivolumab in patients with aRCC who had received prior anti-angiogenic therapy, 
and in 2017, the phase III study CheckMate 214 showed that combined immunotherapy with nivolumab plus ipilimumab resulted 
in greater objective response rate and prolonged progression-free survival when compared with sunitinib in intermediate- and 
poor-risk patients with previously untreated aRCC. Early studies of nivolumab in association with anti-angiogenic therapy have 
generated enthusiasm and multiple combination trials are ongoing.
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Introduction
Renal cell carcinoma (RCC) represents the most common type 
of kidney cancer in adults. The global incidence is approxi-
mately 337,000 cases with 143,000 patients dying of the dis-
ease each year. In 2016, there were an estimated 62,700 cases 
and 12,200 deaths from RCC in the United States alone (1).
In recent years, treatment options have improved signifi-
cantly with the introduction of multiple agents that target 
vascular endothelial growth factor (VEGF) or mammalian 
target of rapamycin (mTOR). These drugs have been ap-
proved based on improvements in progression-free survival 
(PFS) and overall survival (OS). In November 2015, the US 
Food and Drug Administration (FDA) approved nivolumab 
for patients with aRCC who have received prior anti-angio-
genic therapy after showing a statistically significant and clin-
ically meaningful difference in OS (2). Nivolumab is a PD-1 
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checkpoint inhibitor that selectively blocks the interaction 
between the PD-1 expressed on activated T-cells and its two li-
gands, PD-L1 and PD-L2. By disrupting the PD-1/PDL1 sig-
naling, nivolumab is thought to restore the immune response 
and antitumor activity (3). In this mini review, we discuss 
practical considerations for the use of nivolumab in aRCC.
Brief History of Immunotherapy in RCC with 
Interleukin 2 (IL-2) and Interferon-Alpha (IFN-α)
In the late 19th century, William Coley, haunted by the death 
of a patient with metastatic sarcoma, found 47 case reports in 
which concomitant infection seemed to cause the remission 
of an otherwise incurable malignancy. By 1891, Coley began 
injecting his patient’s tumors with heat-killed Streptococcus 
pyogenes and Serratia marcescens, and achieved durable com-
plete remissions in several different types of malignancies (4). 
Since that time, with exponential advances in the understand-
ing of the immune system, the idea of immunotherapy has 
returned to prominence.
Several observations, including the regression of metasta-
ses observed in RCC patients after nephrectomy, suggested 
a relationship between RCC and the immune system. These 
observations, together with disappointing results from treat-
ment with cytotoxic chemotherapy (5), and the recognition 
of several immunological dysfunctions in patients with RCC 
(6), generated significant interest in the development and 
clinical application of immunotherapy.
IL-2 was first identified in 1976 as a T-cell growth factor; 
it mediates its biologic effect by binding to the IL-2 recep-
tor on activated T-cells promoting the clonal expansion of 
antigen-specific cells and plays an important role in potenti-
ating the cytotoxic activity of lymphocytes (7). In the 1980s, 
a series of reports from the National Cancer Institute (8) 
demonstrated that recombinant IL-2 was capable of medi-
ating the regression of tumors in patients with metastatic or 
unresectable malignancies that had previously not responded 
to conventional treatment.
The pooled results of seven phase II studies led to the 
FDA approval of IL-2 therapy in 1992. The reported overall 
response rate was 15% and the complete response rate was 
7%. The responses were durable, with a median duration of 
54 months. Among the patients who achieved a complete re-
sponse, 83% remained free of recurrence at last follow-up (9, 
10). Subsequent large randomized trials continued to show 
response rates of approximately 20% but failed to demon-
strate an OS advantage (11, 12).
IL-2 is a strong stimulator of proinflammatory cytokines 
and is associated with severe toxicity such as capillary leak 
syndrome, cardiac arrhythmias, renal failure, and life-threat-
ening skin reactions. Despite the remarkable responses seen 
in a minority of patients, the need for hospitalization at ex-
pert immunotherapy centers to manage the side effects of its 
administration significantly limited its utilization (13).
A second cytokine that is widely used in the treatment 
of  RCC is IFN-α, a pleotrophic protein with antiviral, im-
munomodulatory, and antiproliferative activities. In 1983, 
successful treatment of  aRCC with IFN-α (14) provided 
the basis for multiple phase II studies using human lym-
phoblastoid interferon and the development of  recombi-
nant interferons. The activity of  IFN-α in aRCC was later 
evaluated in a variety of  large trials. These studies include 
comparisons with noncytokine-containing and other cy-
tokine-containing regimens. The overall response rate 
ranges between 10 and 15% (15). The median improvement 
of  OS was 3.8 months in a meta-analysis of  four studies 
that included 644 patients (16).
Combinations of IFN-α with IL-2, bevacizumab, or 
chemotherapy did not result in substantial further clinical 
benefits and therefore immunotherapy with IL-2 or IFN-α 
was considered to be the standard of care for aRCC despite 
modest improvements in survival until 2005 when sorafenib, 
the first orally active multikinase inhibitor, received FDA ap-
proval. Since then, targeted agents have been the backbone of 
most therapeutic strategies in aRCC with objective response 
rates ranging from 30 to 47% in untreated patients, and from 
1.8 to 23% in pretreated patients (17–20).
Ultimately, resistance to targeted therapy develops and 
toxicity often leads to discontinuation of treatment, limiting 
the clinical benefits of these treatments (21).
Nivolumab provides a novel therapy option for patients 
with aRCC. Its mechanism of action differs from other tar-
geted therapies. It is a fully human IgG4 anti-PD-1 antibody 
that selectively blocks the interaction between PD-1 and its 
ligands PD-L1 and PD-L2 restoring the anticancer immune 
response (22).
PD-L1 Expression in RCC and Prognostic 
Significance
Tumor PD-L1 expression has not been found to be a marker 
of  OS benefit in patients with aRCC treated with nivolumab 
(23). Although associations between tumor PD-L1 ex-
pression and improved outcomes have been observed with 
nivolumab in metastatic melanoma and non-small cell lung 
cancer (24), the predictive role of  PD-L1 status on treat-
ment outcomes remains to be determined. Many limitations 
have appeared with the use of  PD-L1 expression as a po-
tential biomarker for nivolumab activity. This is an area of 
ongoing research as there is currently a lack of  identified 
biomarkers that reliably predict treatment benefit with im-
mune checkpoint inhibitors (25).
Nivolumab versus Everolimus Second-Line Study 
that Led to FDA Approval
In a phase II dose-ranging trial involving patients with 
metastatic RCC, the PD-1 inhibitor nivolumab was found 
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to produce objective responses in 20–22% of  patients with 
an OS ranging between 18.2 and 25.5 months. In the piv-
otal phase III study CheckMate 025, 821 patients with 
aRCC who received previous anti-angiogenic therapy were 
randomized to receive nivolumab 3 mg/kg every 2 weeks or 
everolimus 10 mg daily. Fifty percent of  the patients had an 
intermediate prognosis and 15% a poor prognosis based on 
the Memorial Sloan Kettering Cancer Center risk assess-
ment. In this study, the objective response rate (ORR) was 
greater with nivolumab (25% vs. 5%) and the OS was 25.0 
vs. 19.6 months favoring nivolumab. Grade 3 or 4 treat-
ment-related adverse events were lower in the nivolumab 
group (23). The results of  this study led to its FDA ap-
proval in 2015.
Adverse Events and their Management
Immune checkpoint inhibition is associated with a unique 
spectrum of side effects termed immune-related adverse 
events (irAEs), for example, endocrinopathies, diarrhea, coli-
tis, hepatitis, pneumonitis, interstitial nephritis, and rash (26). 
These are typically transient, but occasionally can be moder-
ate or severe. The incidence of irAEs can be unpredictable, 
and continuous vigilance for symptoms suggestive of irAEs is 
recommended. In general, many toxicities can be detected by 
routine blood work, and liver, kidney, and thyroid functions 
should be closely monitored. Management of irAEs can in-
clude either the use of corticosteroid immunosuppression or 
interruption of the checkpoint inhibitor. Further research is 
required to advance our understanding of the mechanisms 
underlying the development of these toxicities and improve 
upon current management strategies (27). In a phase I study, 
nivolumab was generally well tolerated, with 83% of patients 
developing adverse events but only 11% developing grade 3/4 
toxicity (24). This favorable safety profile was later confirmed 
in the phase II and phase III trials (23, 28). The most com-
mon toxicity was fatigue, occurring in 33% of patients, fol-
lowed by nausea (14%), diarrhea (12%), decreased appetite 
(12%), pruritus (14%), and rash (10%).
Nivolumab Plus Ipilimumab in the Front Line
Escudier et al. (29) presented the findings from the phase III, 
open-label CheckMate 214 study at the ESMO 2017 Con-
gress. In this trial, patients were randomized 1:1 to nivolumab 
(3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for four 
doses, followed by nivolumab, 3 mg/kg every 2 weeks; or to 
receive oral sunitinib, 50 mg a day for 4 weeks in 6-week cy-
cles. Combined immunotherapy with nivolumab plus ipili-
mumab resulted in greater ORR and prolonged PFS when 
compared with sunitinib in intermediate- and poor-risk pa-
tients with previously untreated aRCC.
After 17.5 months of follow-up, ORR in intermediate- /
poor-risk patients was 41.6% for the nivolumbab/ipilimumab 
combination compared with 26.5% for sunitinib. Around 
9.4% of patients receiving the combination therapy achieved 
complete response compared with 1.2% of patients receiving 
sunitinib. Median PFS was 11.6 months for the nivolumab and 
ipilimumab combination versus 8.4 months with sunitinib.
Greater benefit was observed in patients with higher levels 
of PD-L1 expression at baseline. The ORR significantly fa-
vored nivolumab plus ipilimumab over sunitinib in interme-
diate- /poor-risk patients having a baseline PD-L1 expression 
≥1% (58% vs. 25%, P = 0.0002). Median PFS was also signifi-
cantly prolonged (22.8 months vs. 5.9 months, P < 0.0001). 
Patients with PD-L1 expression <1% did not benefit from the 
combination (HR, 1.00; P = 0.9670) (29).
Future Directions
Checkmate 016 investigated nivolumab in association with 
VEGF inhibition with sunitinib or pazopanib. The ORR 
was 52% in the sunitinib arm and 45% in the pazopanib arm. 
Grade 3/4 treatment-related adverse events were observed 
in 82% of patients receiving nivolumab and sunitinib and in 
70% of patients receiving nivolumab and pazopanib. Thir-
ty-six percent of patients in the sunitinib arm and 25% in 
the pazopanib arm had to discontinue therapy. Most of the 
grade 3/4 adverse events were related to transaminitis/hepa-
totoxicity (30). These early studies have generated some en-
thusiasm and multiple combination trials of immunotherapy 
with or without VEGF-targeted therapy are ongoing.
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